ALXN Alexion Pharmaceuticals Inc

Price (delayed)

$159.73

Market cap

$34.96B

P/E Ratio

36.97

Dividend/share

N/A

EPS

$4.32

Enterprise value

$35.46B

Sector: Healthcare
Industry: Biotechnology

Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome and paroxysmal nocturnal ...

Highlights

ALXN's revenue is up by 24% year-on-year and by 6% since the previous quarter
The company's gross profit rose by 23% YoY and by 5% QoQ
ALXN's price to earnings (P/E) is 98% higher than its last 4 quarters average of 18.7 but 57% lower than its 5-year quarterly average of 85.0
ALXN's net income is down by 35% year-on-year but it is up by 13% since the previous quarter
The company's quick ratio fell by 25% QoQ and by 8% YoY
The debt rose by 6% QoQ and by 2.5% YoY

Key stats

What are the main financial stats of ALXN
Market
Shares outstanding
218.85M
Market cap
$34.96B
Enterprise value
$35.46B
Valuations
Price to earnings (P/E)
36.97
Price to book (P/B)
3.16
Price to sales (P/S)
5.97
EV/EBIT
52.21
EV/EBITDA
34.62
EV/Sales
6.05
Earnings
Revenue
$5.86B
EBIT
$679.1M
EBITDA
$1.02B
Free cash flow
$2.62B
Per share
EPS
$4.32
Free cash flow per share
$11.96
Book value per share
$50.53
Revenue per share
$26.76
TBVPS
$42.86
Balance sheet
Total assets
$17.55B
Total liabilities
$6.47B
Debt
$2.77B
Equity
$11.07B
Working capital
$3.74B
Liquidity
Debt to equity
0.25
Current ratio
3.81
Quick ratio
2.81
Net debt/EBITDA
0.49
Margins
EBITDA margin
17.5%
Gross margin
91.2%
Net margin
16.3%
Operating margin
10%
Efficiency
Return on assets
5.5%
Return on equity
8.6%
Return on invested capital
8.3%
Return on capital employed
4.2%
Return on sales
11.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALXN stock price

How has the Alexion Pharmaceuticals stock price performed over time
Intraday
1.18%
1 week
1.93%
1 month
3.85%
1 year
43.38%
YTD
2.23%
QTD
2.23%

Financial performance

How have Alexion Pharmaceuticals's revenue and profit performed over time
Revenue
$5.86B
Gross profit
$5.35B
Operating income
$585.8M
Net income
$956.6M
Gross margin
91.2%
Net margin
16.3%
ALXN's operating margin has dropped by 71% year-on-year but it is up by 22% since the previous quarter
The operating income has plunged by 64% YoY but it has grown by 30% from the previous quarter
The net margin fell by 47% YoY but it rose by 7% QoQ
ALXN's net income is down by 35% year-on-year but it is up by 13% since the previous quarter

Growth

What is Alexion Pharmaceuticals's growth rate over time

Valuation

What is Alexion Pharmaceuticals stock price valuation
P/E
36.97
P/B
3.16
P/S
5.97
EV/EBIT
52.21
EV/EBITDA
34.62
EV/Sales
6.05
ALXN's price to earnings (P/E) is 98% higher than its last 4 quarters average of 18.7 but 57% lower than its 5-year quarterly average of 85.0
The EPS has declined by 34% year-on-year but it is up by 15% since the previous quarter
ALXN's P/B is 50% above its last 4 quarters average of 2.1 and 9% above its 5-year quarterly average of 2.9
Alexion Pharmaceuticals's equity has increased by 7% YoY and by 6% from the previous quarter
ALXN's P/S is 39% above its last 4 quarters average of 4.3 but 16% below its 5-year quarterly average of 7.1
ALXN's revenue is up by 24% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is Alexion Pharmaceuticals business performance
Alexion Pharmaceuticals's return on invested capital has shrunk by 70% YoY but it has increased by 15% QoQ
The ROS has dropped by 66% year-on-year but it is up by 20% since the previous quarter
Alexion Pharmaceuticals's ROA has decreased by 47% YoY but it has increased by 10% from the previous quarter
Alexion Pharmaceuticals's ROE has decreased by 42% YoY but it has increased by 12% from the previous quarter

Dividends

What is ALXN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALXN.

Financial health

How did Alexion Pharmaceuticals financials performed over time
ALXN's total assets is 171% higher than its total liabilities
ALXN's total liabilities is up by 46% year-on-year and by 4.2% since the previous quarter
The company's quick ratio fell by 25% QoQ and by 8% YoY
The debt is 75% lower than the equity
Alexion Pharmaceuticals's equity has increased by 7% YoY and by 6% from the previous quarter
The debt rose by 6% QoQ and by 2.5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.